Journées POLEPHARMA
du Biotesting -2ème édition
11-12 & 18-19 mars 2021
#Stratégies analytiques pour accélérer le développement des biothérapies
PathoQuest
Partenaire Gold
En savoir plus
YOUR GENOMIC EXPERT FOR BIOLOGICS TESTING
Robust and efficient Quality Control testing is critical for the development of biologics in order to reduce time to market and improve patient outcomes.
Developers and producers need QC testing solutions that help de-risk their product development pipeline by preventing adventitious agent contamination and cell line misidentification.
To meet those objectives, PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process. This innovative approach allows for a robust and unambiguous level of testing and for faster turnaround time and is available with GLP grade.
PATHOQUEST NGS SOLUTIONS IN 5 QUICK FACTS:
- PathoQuest is a French biotech based in Paris and soon a US based site in Pennsylvania
- It was created in 2010 as Spin-off of Institut Pasteur
- The company has developed NGS applications for the QC of biological drugs (ATMP, Vaccines, antibodies…) allowing robust and fast analysis under GLP grade.
- PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
- The company provides its services to more than 40 customers worldwide (Biotech, Pharma and CDMO)
Request the full brochure at welcome@pathoquest.com
PathoQuest: Fast and Validated Solutions for QC testing
Keen on learning more about challenges for adventitious virus detection and how standardized NGS method is the solution for the qualification of your biological production?
PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process.
OUR SERVICES
VIRAL SAFETY
PathoQuest’s NGS-based adventitious virus testing approach uses a process called metagenomics to provide sensitive and comprehensive services for the identification of pathogens.
GENETIC CHARACTERIZATION
PathoQuest’s NGS-based genetic characterization testing approach uses the power and robustness of high-throughput sequencing to provide a comprehensive approach to the characterization of biologics intermediates, vaccines, and cell & gene therapy products.
COMPREHENSIVE QUALITY CONTROL FOR BIOLOGICS
PathoQuest NGS innovative approach provides biotech and biopharma companies developing advanced therapy medicinal products (ATMPs), vaccines and other biologicals with robust and unambiguous level of testing and with faster turnaround time.
OUR EXPERTS
Greater detection for better decisions
OUR SERVICE
Customized, fast, reliable, cost-effective
YOUR PRODUCTS
VACCINES
– Broad range detection of viruses
– Genetic drift of vaccine stocks
– Assess highly concentrated stocks
BIOLOGICS
– Trancriptomic NGS approach on MCB
– Reduce the risk of false positives
– Identity & Clonality documentation
GENE & CELL THERAPY
– Signature of viral replication
– High precision genetic characterization
– Insertion site / flanking regions sequencing
YOUR BENEFIT
Ensure the highest safety for your biologic products by de risking the drug development pipeline.
Vos contacts:
Pour tout renseignement lié à votre participation
Naima MEHARZI
naima.meharzi@polepharma.com
Responsable R&D Innovation
Pour tout renseignement lié à l'organisation :
Dana LEGRAIN
dana.legrain@polepharma.com
Responsable Pôle Evénementiel
Luana COSTA
luana.costa@polepharma.com
Chargée de mission événements & réseau
Nos réseaux sociaux
La France s’est fixé pour priorité d’assurer sa souveraineté sanitaire. Pour y arriver, elle doit regagner son leadership européen et accélérer la transition de son industrie (bio)pharmaceutique. Seule une action collective, permettra de relever ces défis.
Polepharma structure la filière industrielle (bio)pharmaceutique française et accompagne sa transformation depuis 20 ans.
POLEPHARMA
21 rue de Loigny la Bataille
28000 Chartres
Tél. : +33 (0)2 37 20 99 90
Mail : contact@polepharma.com